Author: Qiu, Yingshan; Lam, Jenny K. W.; Leung, Susan W. S.; Liang, Wanling
Title: Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside Document date: 2016_9_20
ID: 04pp3lv0_60
Snippet: COPD is a persistent lung disease characterized by irreversible chronic airflow limitation. The disease is usually progressive and associated with an increased chronic inflammatory response in the lungs [205, 206] . It is the result of long term exposure to air pollutants and usually associated with cigarette smoking [205] . It affects around 10% of the population in the world. It is the fourth leading cause of death in most of the industrialized.....
Document: COPD is a persistent lung disease characterized by irreversible chronic airflow limitation. The disease is usually progressive and associated with an increased chronic inflammatory response in the lungs [205, 206] . It is the result of long term exposure to air pollutants and usually associated with cigarette smoking [205] . It affects around 10% of the population in the world. It is the fourth leading cause of death in most of the industrialized countries and expected to become the third by 2020 [207] . Three classes of medications used to manage COPD are bronchodilators (including β 2 -adrenergic receptor and anticholinergic drugs), corticosteroids and phosphodiesterase-4 inhibitor. They are effective in relieving the symptoms of COPD, but none of them can reverse the progressive deterioration in lung function or cure the disease [4, 205] . It is desirable to develop a novel therapy that can simultaneously control the symptoms and improve the long-term prognosis of the disease.
Search related documents:
Co phrase search for related documents- airflow limitation and chronic airflow limitation: 1, 2, 3, 4, 5, 6, 7, 8
- airflow limitation and chronic lung inflammatory response: 1
- airflow limitation and cigarette smoking: 1, 2, 3
- airflow limitation and COPD symptom: 1, 2
- airflow limitation and death leading cause: 1, 2, 3
- airflow limitation and fourth death leading cause: 1
- airflow limitation and inflammatory response: 1, 2, 3, 4, 5, 6, 7
- chronic airflow limitation and death leading cause: 1, 2
- chronic airflow limitation and fourth death leading cause: 1
- chronic airflow limitation and inflammatory response: 1, 2, 3
- chronic lung inflammatory response and death leading cause: 1, 2
- chronic lung inflammatory response and inflammatory response: 1, 2, 3, 4, 5, 6
- cigarette smoking and COPD symptom: 1
- cigarette smoking and death leading cause: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cigarette smoking and fourth death leading cause: 1, 2
- cigarette smoking and inflammatory response: 1, 2, 3, 4, 5, 6
- COPD symptom and inflammatory response: 1
- death leading cause and fourth death leading cause: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- death leading cause and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
Co phrase search for related documents, hyperlinks ordered by date